Compared with solvent-based paclitaxel, albumin-bound nab-paclitaxel exhibits 10-fold higher mean Cmax of free paclitaxel and preclinical models have shown higher drug concentration to tumors and enhanced cell transport.
Updated results from the ongoing global phase 2 study with crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC).
Rapidly evolving sequencing technologies characterizing the cancer genome have shown that not only do germline and somatic alterations in DNA mediate genesis and progression of cancer, but they also are clinically important as diagnostic markers and therapeutic targets.
LUX-Lung 3, the largest prospective trial in patients with EGFR-mutation–positive advanced adenocarcinoma of the lung and the first pivotal trial in Asian and non-Asian patients with EGFR mutations, found afatinib significantly prolonged progression-free survival (PFS).
Low-dose CT screening may benefit individuals at an increased risk for lung cancer; however, uncertainty exists about the potential harms of screening and the generalizability of the results.
High-dose radiation therapy does not improve overall survival (OS) versus a standard radiotherapy dose in patients with locally advanced non−small-cell lung cancer (NSCLC); however, intensity modulated radiotherapy (IMRT) may lead to a better OS rate in patients with stage III disease.
KRAS is the most common driver mutation observed in lung cancer. Discovered in the 1980s, KRAS mutations were initially stereotyped in the literature as occurring primarily in heavy smokers.
Patients and their families often have a limited understanding of their illness and an inaccurate view of their prognosis; and patients face difficult decisions about their cancer treatment and end-of-life care. Yet, with increasing use of personalized therapy, survival can only increase.